Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 85, Issue 3 PART A, 2013, Pages 356-364

  Gomes Da Silva, Lígia C ^a,b   Ramalho, José S ^c   Pedroso De Lima, Maria C ^a,d   Simões, Sérgio ^a,b   Moreira, João N ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Gene silencing; Nanotechnology; Paclitaxel; PLK1; Prostate cancer; siRNA

Indexed keywords

F3 TARGETED LIPOSOME; LIPOSOME; MESSENGER RNA; NANOCARRIER; PACLITAXEL; POLO LIKE KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL ENCAPSULATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; MICROVASCULAR ENDOTHELIAL CELL; MITOSIS INHIBITION; PH; PROSTATE CANCER;

1, 2-DIOLEOYL-3-TRIMETHYLAMMONIUM-PROPANE; 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE; 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE; 12-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE-N-[MALEIMIDE (POLYETHYLENE GLYCOL)(2000)] AMMONIUM SALT; C(16)-CERAMIDE MPEG(2000); CHEM; CHOL; CHOLESTEROL; CONTROL; CTR; DOPE; DOSE REDUCTION INDEX; DOTAP; DRI; DSPC; DSPE-PEG-MAL; EGFP; ENHANCED GREEN FLUORESCENT PROTEIN; G2/M PHASES; G2/MITOSIS PHASES; GENE SILENCING; HALF MAXIMAL DEATH CONCENTRATION; HMEC-1; HUMAN MICROVASCULAR ENDOTHELIAL CELLS; IC(50); N-PALMITOYL-SPHINGOSINE-1-[SUCCINYL(METHOXYPOLYETHYLENE GLYCOL)(2000)]; NANOTECHNOLOGY; PACLITAXEL; PBS; PC3; PC3 PROSTATE CANCER CELLS; PHOSPHATE BUFFER SALINE; PLK1; POLO-LIKE KINASE 1; PROSTATE CANCER; SCHOLESTERYL HEMISUCCINATE; SD; SIRNA; SMALL-INTERFERING RNA; STANDARD DEVIATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE PROTEINS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; ENDOTHELIAL CELLS; G2 PHASE CELL CYCLE CHECKPOINTS; GENE SILENCING; HUMANS; INHIBITORY CONCENTRATION 50; LIPOSOMES; MALE; MITOSIS; PACLITAXEL; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84888308868     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.04.007     Document Type: Article

References (41)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J. Clin. 61 2011 69 90
2. S.H. Lang, F.M. Frame, and A.T. Collins Prostate cancer stem cells J. Pathol. 217 2009 299 306
3. Y. Gan, M.G. Wientjes, and J.L. Au Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors Pharm. Res. 23 2006 1324 1331
4. G. Ploussard, B. Paule, L. Salomon, Y. Allory, S. Terry, D. Vordos, A. Hoznek, F. Vacherot, C.C. Abbou, S. Culine, and A. de la Taille Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life Prostate Cancer Prostatic Dis. 13 2010 97 101
5. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
6. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
7. B. Spankuch, S. Heim, E. Kurunci-Csacsko, C. Lindenau, J. Yuan, M. Kaufmann, and K. Strebhardt Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo Cancer Res. 66 2006 5836 5846
8. B. Spankuch, E. Kurunci-Csacsko, M. Kaufmann, and K. Strebhardt Rational combinations of siRNAs targeting Plk1 with breast cancer drugs Oncogene 26 2007 5793 5807
9. D.S. Benoit, S.M. Henry, A.D. Shubin, A.S. Hoffman, and P.S. Stayton PH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1 Mol. Pharm. 7 2010 442 455
10. K. Strebhardt, and A. Ullrich Targeting polo-like kinase 1 for cancer therapy Nat. Rev. Cancer 6 2006 321 330
11. S. Reagan-Shaw, and N. Ahmad Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer FASEB J. 19 2005 611 613
12. W. Weichert, G. Kristiansen, K.J. Winzer, M. Schmidt, V. Gekeler, A. Noske, B.M. Muller, S. Niesporek, M. Dietel, and C. Denkert Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications Virchows Arch. 446 2005 442 450
13. W. Weichert, G. Kristiansen, M. Schmidt, V. Gekeler, A. Noske, S. Niesporek, M. Dietel, and C. Denkert Polo-like kinase 1 expression is a prognostic factor in human colon cancer World J. Gastroenterol. 11 2005 5644 5650
14. Y.B. Feng, D.C. Lin, Z.Z. Shi, X.C. Wang, X.M. Shen, Y. Zhang, X.L. Du, M.L. Luo, X. Xu, Y.L. Han, Y. Cai, Z.Q. Zhang, Q.M. Zhan, and M.R. Wang Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma Int. J. Cancer 124 2009 578 588
15. Y. Qian, E. Hua, K. Bisht, S. Woditschka, K.W. Skordos, D.J. Liewehr, S.M. Steinberg, E. Brogi, M.M. Akram, J.K. Killian, D.C. Edelman, M. Pineda, S. Scurci, Y.Y. Degenhardt, S. Laquerre, T.A. Lampkin, P.S. Meltzer, K. Camphausen, P.S. Steeg, and D. Palmieri Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain Clin. Exp. Metastasis 2011
16. D.P. Han, J.T. Cui, A.G. Lu, X.H. Chen, B. Feng, Y.P. Zong, S. Qu, Q.F. Cao, and M.H. Zheng Influence of silencing Polo-like kinase 1 on migration and invasion of colorectal cancer cells Zhonghua Wei Chang Wai Ke Za Zhi 14 2011 61 64
17. G.J. Kops, B.A. Weaver, and D.W. Cleveland On the road to cancer: aneuploidy and the mitotic checkpoint Nat. Rev. Cancer 5 2005 773 785
18. B. Spankuch-Schmitt, J. Bereiter-Hahn, M. Kaufmann, and K. Strebhardt Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells J. Natl. Cancer Inst. 94 2002 1863 1877
19. W.J. Xu, S. Zhang, Y. Yang, N. Zhang, W. Wang, S.Y. Liu, H.W. Tian, L. Dai, Q. Xie, X. Zhao, Y.Q. Wei, and H.X. Deng Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo Cancer Biother. Radiopharm. 26 2011 427 436
20. R. Guan, P. Tapang, J.D. Leverson, D. Albert, V.L. Giranda, and Y. Luo Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals Cancer Res. 65 2005 2698 2704
21. A.D. Judge, M. Robbins, I. Tavakoli, J. Levi, L. Hu, A. Fronda, E. Ambegia, K. McClintock, and I. MacLachlan Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice J. Clin. Invest. 119 2009 661 673
22. M. Nogawa, T. Yuasa, S. Kimura, M. Tanaka, J. Kuroda, K. Sato, A. Yokota, H. Segawa, Y. Toda, S. Kageyama, T. Yoshiki, Y. Okada, and T. Maekawa Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer J. Clin. Invest. 115 2005 978 985
23. A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, and C.C. Mello Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391 1998 806 811
24. S.M. Elbashir, W. Lendeckel, and T. Tuschl RNA interference is mediated by 21- and 22-nucleotide RNAs Genes Dev. 15 2001 188 200
25. D. Castanotto, and J.J. Rossi The promises and pitfalls of RNA-interference-based therapeutics Nature 457 2009 426 433
26. J.N. Moreira, A. Santos, V. Moura, M.C. Pedroso de Lima, and S. Simoes Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing J. Nanosci. Nanotechnol. 8 2008 2187 2204
27. L.C. Gomes-da-Silva, N.A. Fonseca, V. Moura, M.C. Pedroso de Lima, S. Simoes, and J.N. Moreira Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges Acc. Chem. Res. 45 2012 1163 1171
28. L.C. Gomes-da-Silva, Y. Fernandez, I. Abasolo, S. Schwartz, J.S. Ramalho, M.C. Pedroso de Lima, S. Simoes, and J.N. Moreira Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform Nanomedicine (Lond.) 2013
29. K. Porkka, P. Laakkonen, J.A. Hoffman, M. Bernasconi, and E. Ruoslahti A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo Proc. Natl. Acad. Sci. USA 99 2002 7444 7449
30. J.N. Moreira, T. Ishida, R. Gaspar, and T.M. Allen Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity Pharm. Res. 19 2002 265 269
31. M.E. Kleinman, K. Yamada, A. Takeda, V. Chandrasekaran, M. Nozaki, J.Z. Baffi, R.J. Albuquerque, S. Yamasaki, M. Itaya, Y. Pan, B. Appukuttan, D. Gibbs, Z. Yang, K. Kariko, B.K. Ambati, T.A. Wilgus, L.A. DiPietro, E. Sakurai, K. Zhang, J.R. Smith, E.W. Taylor, and J. Ambati Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 Nature 452 2008 591 597
32. W.G. Cho, R.J. Albuquerque, M.E. Kleinman, V. Tarallo, A. Greco, M. Nozaki, M.G. Green, J.Z. Baffi, B.K. Ambati, M. De Falco, J.S. Alexander, A. Brunetti, S. De Falco, and J. Ambati Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth Proc. Natl. Acad. Sci. USA 106 2009 7137 7142
33. L.C. Gomes-da-Silva, A.O. Santos, L.M. Bimbo, V. Moura, J.S. Ramalho, M.C. Pedroso de Lima, S. Simoes, and J.N. Moreira Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment Int. J. Pharm. 434 2012 9 19
34. A. Abdollahi, and J. Folkman Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy Drug Resist. Updat. 13 2010 16 28
35. B. Spankuch-Schmitt, G. Wolf, C. Solbach, S. Loibl, R. Knecht, M. Stegmuller, G. von Minckwitz, M. Kaufmann, and K. Strebhardt Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells Oncogene 21 2002 3162 3171
36. S. Simoes, A. Filipe, H. Faneca, M. Mano, N. Penacho, N. Duzgunes, and M.P. de Lima Cationic liposomes for gene delivery Expert Opin. Drug Deliv. 2 2005 237 254
37. M. Mikhaylova, I. Stasinopoulos, Y. Kato, D. Artemov, and Z.M. Bhujwalla Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA Cancer Gene Ther. 16 2009 217 226
38. L.S. Mendonca, J.N. Moreira, M.C. de Lima, and S. Simoes Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment Biotechnol. Bioeng. 107 2010 884 893
39. S. Trabulo, A.M. Cardoso, T. Santos-Ferreira, A.L. Cardoso, S. Simoes, and M.C. Pedroso de Lima Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents Mol. Pharm. 8 2011 1120 1131
40. X.S. Liu, B. Song, and X. Liu The substrates of Plk1, beyond the functions in mitosis Prot. Cell 1 2010 999 1010
41. V. Moura, Combining targeted and triggered drug delivery to tumor cells and the tumor microenvironment a novel strategy on cancer therapeutics, in: Faculty of Pharmacy, University of Coimbra, 2010, p. 153.